264 related articles for article (PubMed ID: 19544563)
1. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
2. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Lin TY; Bear M; Du Z; Foley KP; Ying W; Barsoum J; London C
Exp Hematol; 2008 Oct; 36(10):1266-77. PubMed ID: 18657349
[TBL] [Abstract][Full Text] [Related]
3. Characterization of STAT3 activation and expression in canine and human osteosarcoma.
Fossey SL; Liao AT; McCleese JK; Bear MD; Lin J; Li PK; Kisseberth WC; London CA
BMC Cancer; 2009 Mar; 9():81. PubMed ID: 19284568
[TBL] [Abstract][Full Text] [Related]
4. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Fossey SL; Bear MD; Lin J; Li C; Schwartz EB; Li PK; Fuchs JR; Fenger J; Kisseberth WC; London CA
BMC Cancer; 2011 Mar; 11():112. PubMed ID: 21443800
[TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
6. Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.
Clemente-Vicario F; Alvarez CE; Rowell JL; Roy S; London CA; Kisseberth WC; Lorch G
PLoS One; 2015; 10(11):e0142007. PubMed ID: 26560147
[TBL] [Abstract][Full Text] [Related]
7. Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Ory B; Baud'huin M; Verrecchia F; Royer BB; Quillard T; Amiaud J; Battaglia S; Heymann D; Redini F; Lamoureux F
Clin Cancer Res; 2016 May; 22(10):2520-33. PubMed ID: 26712686
[TBL] [Abstract][Full Text] [Related]
8. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.
Lee H; Saini N; Parris AB; Zhao M; Yang X
Int J Oncol; 2017 Sep; 51(3):967-974. PubMed ID: 28713919
[TBL] [Abstract][Full Text] [Related]
9. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
Özgür A
J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
[TBL] [Abstract][Full Text] [Related]
10. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
[TBL] [Abstract][Full Text] [Related]
11. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
London CA; Acquaviva J; Smith DL; Sequeira M; Ogawa LS; Gardner HL; Bernabe LF; Bear MD; Bechtel SA; Proia DA
Clin Cancer Res; 2018 Dec; 24(24):6396-6407. PubMed ID: 30171047
[TBL] [Abstract][Full Text] [Related]
12. ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma.
Cam M; Gardner HL; Roberts RD; Fenger JM; Guttridge DC; London CA; Cam H
Oncotarget; 2016 Jul; 7(30):48533-48546. PubMed ID: 27391430
[TBL] [Abstract][Full Text] [Related]
13. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
14. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells.
Lee DS; Lee MK; Kim JH
Anticancer Res; 2009 Dec; 29(12):5039-44. PubMed ID: 20044614
[TBL] [Abstract][Full Text] [Related]
15. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
16. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
18. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
19. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
